Pediatric Cancer News
After a cancer diagnosis, male adolescents may be unprepared to make decisions about fertility preservation independently and instead need parental involvement.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
Although the number of reported cases of SARS-CoV-2 infection among pediatric patients with cancer has been low, the effect of the pandemic on cancer care services for this population is not well understood.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Ruxolitinib, a selective nonreceptor Janus kinase 1/2 inhibitor shown to have activity in adults with refractory GVHD, was studied in pediatric patients.
An evaluation of a large dataset sought to determine use of imaging studies in children treated in children’s hospital emergency departments.
Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.
Investigators assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors.
Population-based study evaluated survival outcomes for patients with cancer diagnosed over a 41-year period.
Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.
Survival from time of recurrence was similar to that seen in younger patients.
Pediatric medulloblastoma demonstrated a distinct methylation profile that could identify the disease and monitor treatment response.
As part of the Zero Childhood Cancer Program, high-risk pediatric tumors were characterized by whole-genome sequencing, RNA sequencing, and methylation profiling.
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%.
The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer.
A large cross-sectional cohort study investigated the relationship between hearing loss and measures of neurocognition in survivors of childhood cancers.
Studies suggest that the majority of pediatric patients with cancer and COVID-19 experience mild disease — rather than severe disease — as a result of infection with the novel virus.